J&J and Eli Lilly Concealed Breast Cancer Risks in Blockbuster Antipsychotics for Decades, Wisner Baum Lawsuit Alleges
Attorneys from Wisner Baum filed the complaint on behalf of plaintiff Bridgett Brown, who was prescribed both brand-name and generic versions of Risperdal and Zyprexa. She was diagnosed with breast cancer in approximately 2024.
This is the first lawsuit to allege that these antipsychotic drugs cause breast cancer. The complaint centers on the drugs' capacity to cause hyperprolactinemia—a hormonal imbalance directly tied to breast cancer development.
Recent studies cited in the lawsuit show significant increased breast cancer risks:
62% increased breast cancer risk for high-prolactin drugs like Risperdal and 54% increased risk for medium-prolactin drugs like Zyprexa – A study of 540,737 women (Rahman, 2023) 59% increased breast cancer risk for Risperdal – A review of 15 studies conducted on over 1 million individuals (Bird, 2025) 47% increased breast cancer risk after 5+ years of exposure to prolactin-increasing antipsychotics like Risperdal and Zyprexa – A Swedish registry study of 132,061 women (Solmi, 2024)
Atypical antipsychotic drugs were initially approved for treating severe schizophrenia. However, the lawsuit alleges the drug manufacturers broadened their customer bases by gaining approval for milder indications and promoting off-label use, including ADD in children and dementia in the elderly, generating billions in profits.
'These companies transformed narrow-use schizophrenia drugs into multi-billion-dollar per year blockbusters by targeting extremely vulnerable segments of our population, all while hiding a cancer risk they've known about for decades,' said Pedram Esfandiary, attorney for Ms. Brown.
The lawsuit alleges that despite knowledge dating back to the 1990s connecting these drugs to hyperprolactinemia, drug labels denied any cancer risk, stating until 2025, 'neither clinical trials nor epidemiological studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans.'
'The science has been clear on prolactin-elevating antipsychotics for decades,' said Monique Alarcon, attorney for Ms. Brown. 'These companies had a duty to inform; they failed, and now individuals nationwide are suffering the consequences. We intend to hold them accountable.'
The lawsuit seeks compensatory and punitive damages, alleging strict liability for failure to warn, negligence, and fraud. The case is Brown v. Johnson & Johnson et al (Case No. 25CV119808). Read the complaint here.
The award-winning law firm of Wisner Baum has successfully litigated cases against many of the largest pharmaceutical companies in the world. Since 1985, the firm has earned a reputation for breaking new legal ground, holding corporations accountable, influencing public policy, and raising public awareness on important safety issues. Using its longstanding tradition of success in the courtroom, the firm always strives to expose unsafe products or harmful practices to protect consumers from dangerous products. The firm has won over $4 billion in settlements and verdicts across all practice areas.
MEDIA CONTACTSteve Crighton, steve@newsroompr.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysia Sun
18 hours ago
- Malaysia Sun
Smart Jelly for Smart Aging: Chula's High-Protein Pudding Takes Global Stage
BANGKOK , Aug. 5, 2025 /PRNewswire/ -- Chulalongkorn University 's "High-Protein Jelly Pudding with Modified Texture for the Elderly with Swallowing Difficulties," developed by Asst. Prof. Dr. Varanya Techasukthavorn and a team from the Faculty of Allied Health Sciences, won a bronze medal in Geneva , along with a special award from Malaysia . Striking with banana and strawberry flavors, the jelly pudding is easy to consume and provides a high protein content of 7-8 grams per cup to strengthen muscles. It's suitable for the elderly, patients, and those who need additional protein. The team is preparing to scale up to commercial production soon. Smart Jelly for Smart Aging Chula's High-Protein Pudding Takes Global Stage The "High Protein Jelly Pudding with Modified Texture for the Elderly with Swallowing Difficulties" by Asst. Prof. Dr. Varanya Techasukthavorn, Department of Nutrition and Dietetics, Faculty of Allied Health Sciences, Chulalongkorn University , and her team won the Bronze Medal at "The 50th International Exhibition of Inventions Geneva," held on April 9-13, 2025 , in Geneva, Switzerland , and the Prize of Malaysia delegation from Malaysia Delegation from Malaysia . This marks another remarkable innovation that addresses the needs of an aging society and the elderly people who often face problems with reduced food consumption and difficulty chewing and swallowing. Elderly-Friendly Protein Snack under IDDSI Standards Asst. Prof. Dr. Varanya Techasukthavorn, head of the research team, revealed the origin of this innovation: elderly people often have trouble chewing and swallowing food, which causes them to receive insufficient nutrients, resulting in muscle loss. Continuous research on food for people with swallowing difficulties has led to the development of "46 swallowing training foods based on international IDDSI standards." This sparked requests for ready-to-eat snacks that are high in nutrients and safe to swallow for the elderly. Hence, the "High Protein Jelly Pudding with Modified Texture for the Elderly with Swallowing Difficulties" was created as a between-meal supplement with delicious flavors that appeal to Thai tastes for elderly people. The product is marketed under the name "Elderine," developed in collaboration with Banpong Novitat Co., Ltd. "The research and development of the high-protein jelly pudding formula took more than 1 year, going through various processes in the laboratory. Experiments were done to modify the texture and enhance nutritional value, adjusting the proportions of raw ingredients and flavors as well as examining the texture. The product was then evaluated by 30 elderly volunteers before undergoing the production technology that best meets the requirements," Asst. Prof. Dr. Varanya stated. 2-in-1 jelly pudding: high-protein and chewable, an innovation for every age Asst. Prof. Dr. Varanya explained the unique characteristic of the newly developed high-protein jelly pudding: "it differs from the jelly pudding sold in the market in that it has a 2-in-1 texture. The ready-to-eat jelly texture maintains its stability on a spoon and can become a soft pudding texture when lightly mashed with a spoon, helping elderly people chew and consume food even without teeth. Moreover, this high-protein jelly pudding contains up to 7 grams of a special whey protein isolate per cup without hardening the texture or making it bitter. It incorporates modified cassava starch with glucose polymer molecules to achieve a low glycemic index, and the texture is optimized with a balanced blend of carrageenan and other gelling agents. Using advanced production technology, the product can be stored at room temperature for up to 6 months while maintaining the same quality and texture. Currently, two flavors have been developed to suit the Thai palate: banana and strawberry. Each cup of jelly pudding provides 70-80 calories of energy and 7-8 grams of easily digestible protein, equivalent to one chicken egg. It serves as a healthy snack that can be consumed up to 2 cups per day. Besides the elderly, the product is suitable for various groups of consumers, e.g., those who have recently had their teeth or wisdom teeth removed, causing difficulty chewing; teenagers who want to increase their protein intake; cancer patients who need a lot of protein supplements; and those who would like to build muscle, etc. This high-protein jelly pudding innovation received support from Dr. Chaiwut Gamonpilas from the National Metal and Materials Technology Center (MTEC), National Science and Technology Development Agency (NSTDA), who conducted an oral tribology test on the texture and slipperiness of the jelly pudding. Toward Medical Food Innovation for the Elderly Currently, this product is in the process of patent application. For the future, Asst. Prof. Dr. Varanya shared plans to register the product as a special-purpose food in the form of medical food. In collaboration with a research team (Asst. Prof. Dr. Pattra Wattanapan from the Faculty of Medicine, Khon Kaen University), a human research study will be conducted to test the effectiveness of the high-protein jelly pudding product on increasing muscle mass in elderly people. The team is also expanding collaboration with a research team from Japan for commercial production of the jelly pudding. It is expected to be available in the market around this coming October. Asst. Prof. Dr. Varanya is committed to studying food products for those with swallowing difficulties, with plans to develop products in other forms, such as Thai desserts for the elderly, as well as functional food products with other added nutrients essential for the elderly, like fiber to help with digestion. For the full release and more images, please visit: About Chulalongkorn University Chulalongkorn University has made the world's top 50 university list for employment outcomes, which reflects both the high employment rate and work ability of Chula graduates. The university is also listed as the best in Thailand for the 15th Consecutive Year (since 2009), according to the newly released QS World University Rankings 2024, putting Chula at 211th in the world, up from 244th last year. Social Media: Facebook: Youtube: Linkedin:
Malaysian Reserve
a day ago
- Malaysian Reserve
Nuna Selected by White House and CMS to Join Landmark Health Tech Ecosystem Initiative
SAN FRANCISCO, Aug. 4, 2025 /PRNewswire/ — Nuna announced its selection to join the Centers for Medicare & Medicaid Services (CMS) Health Tech Ecosystem, a landmark public-private initiative designed to transform healthcare for Americans. The initiative was unveiled at a White House event on Wednesday by President Donald Trump, CMS Administrator Dr. Mehmet Oz, HHS Secretary Robert F. Kennedy Jr., and Amy Gleason, Acting Administrator of DOGE. The event was attended by a select group of healthcare leaders and innovators, including Nuna Founder and CEO, Jini Kim. As part of the ecosystem, Nuna will contribute its expertise to two cornerstone efforts: Conversational AI Assistance and Diabetes & Obesity Prevention and Management. 'We're honored to stand alongside CMS in this bold and necessary step forward in healthcare,' said Jini Kim. 'We believe health isn't just built in the hospital or clinic; it's forged in the small moments of our daily lives. That's why we created Nuna, a trusted digital companion to help people succeed on their health journey, one day at a time.' Nuna's pledge is centered on its AI-powered digital engagement platform. Nuna's app empowers patients to confidently manage their chronic conditions through a combination of 24/7 conversational support, motivating gamification, and direct linkage to their clinical care team. This integrated approach drives powerful results: 72% of users with uncontrolled hypertension achieve control and 73% remain active after six months. By connecting daily patient behavior to the clinical team, Nuna bridges a critical gap in today's healthcare landscape by enabling timely, proactive intervention by care teams for their patients. 'Nuna has been a game changer for patients struggling with chronic conditions,' said David Ansell, MD, of Rush University System for Health and a Nuna development partner. 'It extends care from the clinic to the home and its AI enhanced education engages patients in behavioral change that persists over time. The result being better blood pressure control and improved health behaviors. Early results suggest it can crack the code on chronic disease self-management by engaging people to attend to their health when they are in their homes. This type of tech innovation has great potential to transform primary and preventive care across the US.' About Nuna Nuna is a digital health company dedicated to transforming chronic care by empowering patients and their clinicians. Its AI-driven platform provides personalized, continuous support to help people manage their health and chronic conditions in the moments that matter most. Nuna partners with health systems and health plans to improve patient outcomes, enhance care team efficiency, and reduce the overall cost of care. For more information about Nuna's participation in the CMS Digital Health Ecosystem, visit or contact press@
Malaysian Reserve
4 days ago
- Malaysian Reserve
Elixir MD Launches Australia & New Zealand Subsidiary in Exclusive Partnership with High Tech Medical Pty. Ltd.
IRVINE, Calif. and QUEENSLAND, Australia, Aug. 1, 2025 /PRNewswire/ — ELIXIR MD, Inc., a pioneer in advanced medical technology and proprietary treatment protocols for plastic surgery, today announced the formation of its wholly owned subsidiary in Australia and New Zealand, alongside an exclusive partnership with High Tech Medical Pty Ltd. to launch the ELIXIR MD™ device across the region. Ewan Mohammed, CEO of ELIXIR MD, Inc., stated:'We're proud to join forces with High Tech Medical—Australia and New Zealand's leading medical technology partner—to bring the ELIXIR MD™ device to facial surgery patients across one of the world's fastest-growing cosmetic markets. With more than 25 years of proven commitment to clinical excellence, High Tech Medical brings deep market insight and trusted relationships throughout the aesthetic medical community. Their long-standing success in introducing advanced technologies to Australians and New Zealanders makes them the ideal partner for ELIXIR MD, Inc.' Matt Moncrieff, Managing Director of High-Tech Medical Pty Ltd., added:'High Tech Medical is proud to work exclusively with ELIXIR MD, Inc., Ewan and the entire team have demonstrated a clear commitment to innovation and to reshaping the perioperative care model in plastic surgery. The ELIXIR MD™ device and its proprietary treatment protocols represent a new gold standard in post-surgical recovery by significantly reducing patient downtime and improving outcomes.' Australia and New Zealand: A Rising Market for Surgical Innovation Australian cosmetic surgery market reached approximately $1.8B in 2024, with expected growth to $3.9B by 2033, reflecting a CAGR of ~9.3% (IMARC Group, Rentech Digital). Facial cosmetic surgery—the category where ELIXIR MD™ is uniquely focused—is the fastest-growing segment of the cosmetic surgery market in Australia, with a projected CAGR of approximately 14.1% through 2030 (Grand View Research). Demand for face and eyelid surgeries (e.g. blepharoplasty, facelifts) is rising sharply in Australia and New Zealand, in key part driven by post-weight loss volume depletion and rejuvenation surgery (Daily Telegraph). About High Tech Medical Pty in 1999, High Tech Medical is one of the most respected providers of specialist aesthetic medical devices across Australia and New Zealand. With over two decades of leadership, the company has introduced breakthrough technologies that support minimally invasive treatments, reduce patient risk and downtime, and improve clinical outcomes. High Tech Medical is known for its consultative approach—helping practitioners select and integrate complex, high-performance systems into their practices with confidence. About ELIXIR MD, in Irvine, California, ELIXIR MD, Inc. is a medical technology company redefining recovery in plastic surgery through non-invasive, perioperative innovations. Now operating in 18 markets—including a wholly owned subsidiary in Australia and New Zealand—our FDA-cleared ELIXIR MD™ technology is built to support faster healing and better outcomes for surgeons and their patients worldwide.
